Mycoplasma Testing Market Analysis

Application (Cell Line, Virus Testing, End of Production Testing)

The cell line segment is estimated to gain the largest market share of about 55% in the year 2037. The growth of the segment is expected due to the rising demand for monoclonal antibodies. For instance, monoclonal antibodies have been proven efficient in constraining COVID-19. Anti-SARS-CoV-2 monoclonal antibodies, such as REGEN-COV, have gained success to prevent infection in domestic contacts and to reduce the risk of hospitalization or death associated with COVID-19. Testing cell lines used for monoclonal antibod production ensures the prevention of mycoplasma contamination and interference with cell growth and antibody expression.

Technique (PCR, ELISA, Microbial Culture, Enzymatic Methods)

The PCR segment is expected to garner a tremendous share of around 40% in the year 2037. The PCR technique recognizes the various species of mycoplasma by isolating the additional contaminated DNA. The results gained by the PCR (polymerase chain reaction) technique are highly reliant, moreover, the results are quick to achieve and the technique is easy to use.

Our in-depth analysis of the market includes the following segments:

Application	Cell Line Virus Testing End of Production Testing
Technique	PCR ELISA Microbial Culture Enzymatic Methods
Product & Services	Assays, Kits, & Reagents Instruments Services
End User	Biopharmaceutical Company Cell Banks Contract Research Organization (CROs)

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of mycoplasma testing is estimated at USD 1.2 billion.

The mycoplasma testing market size was valued at USD 1.09 billion in 2024 and is expected to cross USD 4.09 billion by the end of 2037, registering more than 12.3% CAGR during the forecast period i.e., between 2025-2037. Increasing expenditure on new biotech research, advancing technology of mycoplasma testing, and globalization of research will boost the market growth.

North America industry is poised to account 37% revenue share by 2037, owing to rising presence of various biotech and pharmaceutical companies in the region.

The major players in the market include Thermo Fisher Scientific, Inc., Merck KGaA, Lonza Group Ltd., PromoCell GmbH, Asahi Kasei Corporation, Sartorius AG, InvivoGen, Eurofins Scientific, SwiftDx, Agathos Biologics.

Mycoplasma Testing Market Analysis